PixarBio Corporation
Limited financial coverage for PXRB.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
About the company
PixarBio Corporation operates as a specialized pharmaceutical and biotechnology firm, primarily dedicated to the pre-clinical and clinical advancement of neurological drug delivery systems. Initially, their focus is on alleviating post-surgical pain. Beyond this, the company's extensive research and development initiatives encompass crafting innovative delivery platforms for a variety of pharmaceuticals, medical devices, or biological therapies.
- CEO
- Francis M. Reynolds
- IPO
- 2023
- Employees
- 30
- HQ
- US
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -55.70
- Avg Volume
- 54
Get TickerSpark's AI analysis on PXRB
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our PXRB coverage
Recent articles, reports, and earnings notes.
No research on PXRB yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PXRB report →Similar companies
Peers in the same neighborhood.